Literature DB >> 22365757

Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.

Yasushi Yoshikawa1, Kazuya Kobayashi, Shinya Oishi, Nobutaka Fujii, Toshio Furuya.   

Abstract

CXCR4 is a G-protein coupled receptor that is associated with many diseases such as breast cancer metastasis, HIV infection, leukemic disease and rheumatoid arthritis, and is thus considered an attractive drug target. Previously, we identified a cyclic pentapeptide, FC131, that is a potent antagonist for CXCR4. In this study, we constructed a three dimensional model of the CXCR4-FC131 complex. To investigate the backbone flexibility of FC131, we performed molecular dynamics simulations of FC131 based on the NMR structure of FC131, and obtained snapshot structures from the trajectories which were used to model the docking pose of FC131 into CXCR4. Our final model of the CXCR4-FC131 complex is partially different from the X-ray crystal structure of CXCR4-CVX15 and suggests water-mediated interactions. Nevertheless, this docking pose is consistent with the experimental data. We believe our model will aid in the discovery and development of small-molecule antagonists for CXCR4. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365757     DOI: 10.1016/j.bmcl.2012.01.134

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

Review 1.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

Review 3.  Peptide and protein-based inhibitors of HIV-1 co-receptors.

Authors:  Horst A von Recum; Jonathan K Pokorski
Journal:  Exp Biol Med (Maywood)       Date:  2013-05

4.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 5.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting.

Authors:  Chao Xu; Hong Zhao; Haitao Chen; Qinghua Yao
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

6.  Molecular basis for the antagonistic activity of an anti-CXCR4 antibody.

Authors:  Li Peng; Melissa M Damschroder; Kimberly E Cook; Herren Wu; William F Dall'Acqua
Journal:  MAbs       Date:  2016       Impact factor: 5.857

7.  Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.

Authors:  Pandian Sokkar; Mirja Harms; Christina Stürzel; Andrea Gilg; Gönül Kizilsavas; Martina Raasholm; Nico Preising; Manfred Wagner; Frank Kirchhoff; Ludger Ständker; Gilbert Weidinger; Benjamin Mayer; Jan Münch; Elsa Sanchez-Garcia
Journal:  Commun Biol       Date:  2021-09-22

Review 8.  CXCL12 Signaling in the Tumor Microenvironment.

Authors:  Luigi Portella; Anna Maria Bello; Stefania Scala
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Crystal structure of dopamine receptor D4 bound to the subtype selective ligand, L745870.

Authors:  Ye Zhou; Can Cao; Lingli He; Xianping Wang; Xuejun Cai Zhang
Journal:  Elife       Date:  2019-11-21       Impact factor: 8.140

10.  Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.

Authors:  Ali Işbilir; Jan Möller; Marta Arimont; Vladimir Bobkov; Cristina Perpiñá-Viciano; Carsten Hoffmann; Asuka Inoue; Raimond Heukers; Chris de Graaf; Martine J Smit; Paolo Annibale; Martin J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-04       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.